This acquisition for Alcon means a growing ophthalmic portfolio of commercial products and development pipeline.
Alcon completed its purchase of Aerie Pharmaceuticals earlier this month, according to a press release . This transation adds pharmaceutical research and development capabilities, further expanding expertise for future product pipelines, as well as explands Alcon’s presence in the $20 billion global ophthalmic pharmaceutical category. 1
“Alcon has a rich history within the ophthalmic pharmaceutical space rooted in a deep understanding of Eye Care Professionals. We are excited to add Aerie’s significant technical expertise in order to Alcon R& D, which enhances our efforts to build a compelling portfolio associated with ophthalmic pharmaceuticals, ” said David Endicott, CEO of Alcon, in a press release.
Through the transaction, Alcon has added the commercial products Rocklatan (netarsudil and latanoprost ophthalmic solution) 0. 02%/0. 005% plus Rhopressa (netarsudil ophthalmic solution) 0. 02%, as well as AR-15512, the Phase 3 product candidate for dry eye disease.
Alcon offers also acquired a pipeline of ophthalmic pharmaceutical item candidates with the opportunity to leverage Aerie’s existing research and advancement capabilities.
The transaction complements Alcon’s expansion intothe ophthalmic pharmaceutical area, including acquisitions of the exclusive U. S. commercialization rights for Simbrinza from Novartis in April 2021 and Eysuvis plus Inveltys from Kala Pharmaceutical drugs, Inc. within May 2022.
Alcon intends to fully integrate Aerie into its business. As previously disclosed, the company provides used debt to fund the particular transaction with regard to a total purchase consideration of approximately $930 million.
Ophthalmology Drugs Global Market Report 2021: COVID-19 Impact and Recovery in order to 2030.